Share This Page
Drug Price Trends for NDC 59148-0008
✉ Email this page to a colleague
Average Pharmacy Cost for 59148-0008
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ABILIFY 10 MG TABLET | 59148-0008-13 | 18.71019 | EACH | 2025-04-23 |
| ABILIFY 10 MG TABLET | 59148-0008-13 | 18.71325 | EACH | 2025-03-19 |
| ABILIFY 10 MG TABLET | 59148-0008-13 | 18.71225 | EACH | 2025-02-19 |
| ABILIFY 10 MG TABLET | 59148-0008-13 | 18.71225 | EACH | 2025-01-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59148-0008
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 59148-0008
Introduction
The National Drug Code (NDC) 59148-0008 identifies a specific pharmaceutical product within the U.S. healthcare market. Precise insights into its market dynamics and pricing trajectory are essential for stakeholders—including healthcare providers, payers, manufacturers, and investors—to inform strategic decisions. This analysis synthesizes current market conditions, competitive landscape, regulatory factors, and economic trends to project future pricing paths.
Product Overview and Regulatory Context
NDC 59148-0008 corresponds to [Product Name], a [drug class or therapeutic category], indicated for [primary therapeutic use]. As of its latest FDA approval or clearance, its regulatory status influences market entry barriers, patent protections, and biosimilar or generic competition potential.
The regulatory environment also affects reimbursement frameworks under Medicare, Medicaid, and private insurance plans. Key regulatory milestones, such as FDA orphan drug designation or exclusivity periods, can significantly impact market exclusivity and pricing.
Current Market Landscape
Market Size and Indications
The therapeutic area targeted by this drug reflects a sizable and growing market. For example, if it treats a chronic or high-prevalence condition, such as rheumatoid arthritis or certain cancers, the overall market volume may remain expanding due to increasing disease incidence and improved diagnostic rates.
Recent epidemiological data suggest that [disease prevalence] in the U.S. stands at [number], with an annual treatment penetration rate of [percentage]. Treatment adherence and switching patterns also influence the existing pipeline and competitive pressure.
Competitive Environment
The competitive landscape is characterized by:
- Branded drugs offering similar efficacy, potentially with higher prices.
- Generics or biosimilars, which exert downward pricing pressure once exclusivity expires.
- Emerging therapies leveraging novel mechanisms or delivery systems, risking obsolescence of existing treatments.
As of now, [number] competitors are active within this space, with [product names] as the primary alternatives. Patent protections and exclusivities, such as data exclusivity or patent life extensions, delay generic entry, maintaining pricing power for the originator manufacturer.
Market Penetration and Adoption Trends
The initial uptake of NDC 59148-0008 has been influenced by:
- Physician adoption rates
- Insurance formulary placements
- Patient access programs
Early adopters and key opinion leaders tend to accelerate market penetration, while reimbursement hurdles can retard widespread use.
Pricing Overview and Influences
Current Price Point
The current average wholesale price (AWP) or list price for NDC 59148-0008 is approximately $[amount] per [dosage form/period]. Payer-reported net prices typically trend lower, reflecting rebates, discounts, and contractual arrangements.
Pricing Dynamics
Factors affecting current pricing include:
- Regulatory exclusivity periods limiting generics.
- Market demand elasticity for the therapeutic category.
- Cost of production, which in biologics can be significantly higher, influencing price margins.
- Reimbursement policies, particularly in value-based care models, incentivize pricing to demonstrate cost-effectiveness.
Reimbursement Landscape
Insurance coverage policies and drug formulary placements dictate patient access and influence pricing strategies. High-impact drugs often command premium prices if they demonstrate superior efficacy or safety profiles compared to competitors.
Future Price Projections (Next 3-5 Years)
Factors Supporting Price Stability or Increase
- Patent and exclusivity protections are expected to preserve pricing power for [number of] more years.
- Market expansion, driven by increased indications or approved population subsets.
- Limited competition, especially if regulatory or manufacturing hurdles delay biosimilar or generic entry.
Based on current patent expiry estimates, a modest price escalation of 2-4% annually may persist, driven by inflationary pressures and value-based pricing models.
Downward Price Pressure Factors
- Entry of biosimilars or generics, which could reduce prices by 20-40% upon market entry [1].
- Payer negotiations and formulary management, increasingly favoring cost-effective options.
- Healthcare policy reforms emphasizing drug price transparency and value, potentially capping reimbursement levels.
Dynamic Models and Scenario Analysis
- Optimistic Scenario: patent extensions and slow biosimilar adoption sustain prices with minimal erosion—average annual price increases of 2-3%.
- Moderate Scenario: generic entry begins in [year], leading to a 15-25% price reduction over 3 years.
- Pessimistic Scenario: aggressive biosimilar competition and policy interventions cause a 30-40% decrease within 5 years.
Market Growth and Revenue Projections
Given the current market size of $[amount], conservative estimates suggest annual revenue growth of [percentage] over the next five years, assuming stable demand and moderate price increases.
Expanding indications or dosing schedules could further bolster revenues, especially if the drug becomes standard of care in new treatment lines.
Key Market Considerations
- Regulatory exclusivity timelines critically dictate pricing trajectories.
- Competitive innovations may rapidly alter the landscape.
- Pricing strategies must balance profit maximization with payer affordability, especially under value-based models.
- Supply chain stability and manufacturing capacity are vital for maintaining market share.
Key Takeaways
- Patent and exclusivity protections exert a profound influence on current and future pricing levels for NDC 59148-0008.
- Generic and biosimilar competition are pivotal risks that could substantially lower prices within 3-5 years.
- Market expansion through new indications or improved formulation could sustain or enhance revenue streams.
- Payer dynamics and policy shifts towards value-based care will increasingly impact pricing negotiations.
- Strategic planning should incorporate scenario analyses to mitigate risks related to competitive entry and policy changes.
FAQs
Q1: What factors most influence the future pricing of NDC 59148-0008?
A: Patent protections, competitive entry (biosimilars/generics), market demand, regulatory changes, and reimbursement policies primarily shape future prices.
Q2: When is generic or biosimilar competition likely to impact NDC 59148-0008?
A: Typically, 12-14 years post-approval, once patent exclusivity expires or is challenged, biosimilar or generic versions may enter the market, potentially reducing prices significantly.
Q3: How does the regulatory landscape affect pricing strategies?
A: Regulatory decisions, such as granting exclusivity, approving new indications, or fast-tracking biosimilars, directly influence how high or low the price can be maintained.
Q4: What role do healthcare policies play in price projections?
A: Policies promoting drug affordability, transparency, and value-based care can pressure manufacturers to justify higher prices or implement differential pricing strategies.
Q5: How should stakeholders prepare for potential price reductions?
A: Diversify revenue streams through indications expansion, invest in patient access programs, negotiate favorable payer contracts, and monitor patent and regulatory developments.
References
[1] US Food and Drug Administration. "Biosimilar and Interchangeable Products." 2022.
[2] IQVIA. The Impact of Biosimilar Entry on Prescription Drug Prices. 2022.
[3] American Journal of Managed Care. "Regulatory and Market Factors Affecting Biologic Price Trends." 2021.
[4] Centers for Medicare & Medicaid Services. "Drug Pricing and Reimbursement Policies." 2022.
More… ↓
